Call text

Third transnational call for research projects within the JPIAMR

To unravel the dynamics of transmission and selection of antimicrobial resistance (AMR) at the genetic, bacterial, animal, human, societal, and environmental levels, in order to design and evaluate preventive and intervening measures for controlling resistance.

1. Aim of the call:

The primary aim of the third joint call of JPIAMR is to combine the resources, infrastructures, and research strengths of multiple countries in order to address transmission of antibiotic resistance following a 'One Health Approach'. The goal is to foster multinational research collaborations to add value to and to build upon the research conducted independently at national level and to work together to improve the control of resistant bacterial infections of clinical and/or veterinary importance only.

An organism develops resistance to a drug either by a gene mutation or by the acquisition of genetic components from another strain (i.e. transmission of resistance). Resistant organisms can multiply in the presence of a drug (i.e. selection of resistance traits) but without transmission, resistance would remain an isolated problem.

To understand the complex biological and environmental interactions that shape the spread of antibiotic resistance, we must identify and characterise the determinants that contribute to the spread of resistance in and between different reservoirs; including humans (sick and healthy people), animals (livestock, companion and wild animals) and the environment (indoor and outdoor).

Investigating the complex biology and epidemiology of selection and transmission of resistance is crucial in order to design preventive measures to address this public threat. The success and abundance of antibiotic resistant bacterial strains with particular public health importance should be determined through the development of risk assessment approaches that are based on the genomic repertoire of bacterial pathogens and the ecological constraints that determine their fitness in clinical, community, veterinary, and environmental settings.

We expect that most collaborations will be multidisciplinary with expertise that could include, but are not limited to, bacteriologists (clinical, veterinary, and environmental), chemists, ecologists, mathematicians, informatics and computational modellers, medical practitioners (human and veterinary), etc., where appropriate. Consortia are encouraged to include participants from academia, medical and public health practitioners (both human and veterinary), policy makers, and industry, where appropriate (please note the national/regional regulations).

Only multinational projects will be funded. Each proposal must involve a minimum of three (3) countries participating in this call and a maximum of six (6) project participants (see 2.1 Eligibility criteria for further details).

Submissions of proposals will be in two steps: The deadline for submitting pre-proposals is **March 21st, 2016** and invited full proposals must be submitted by **July 4th, 2016**. Projects will be expected to start at the **end of 2016 or beginning of 2017**. Funding will be granted for a maximum of three years.

1.1 Call Topics:

- To understand the acquisition, persistence/ retention, and transmission of resistant organisms and resistance genes, research should investigate:
    - Selection of resistance and its transmission between individuals and between human and non-human sources
    - The success of clones, organisms, and resistance patterns and the role of different genetic elements.
    - The fitness of the resistant bacteria in clinical, community, veterinary, and environmental settings.

- In order to identify and target better prevention measures and management practices to control resistance, research in the following areas are needed:
    - Quantitative multilevel modelling to understand the dissemination of AMR between different environments (here the "environment" is seen in its broadest sense from the host to man-made settings and natural environments)
    - Risk assessment studies to estimate which transmission pathways from the environment (indoor and outdoor) and/or animals to humans are the most important to control in order to minimise the transfer of resistant organisms.
    - Explore potential interventions and mitigation strategies, including new strategies, which minimise the emergence, transmission, and/or exposure risk of resistance in clinical, veterinary, community and environmental settings in a cost-effective, sustainable way.

Proposals submitted may include, but are not limited to, the following types of research:

- Multidisciplinary studies investigating the molecular mechanisms that lead to the emergence, acquisition, persistence/ retention, and transmission of AMR
- Development or use of appropriate animal models to study the selection and transmission of AMR within the host.
- Investigation of specific drivers of the emergence, evolution and co-selection of resistance; e.g. optimisation of dosing strategies to minimise impact on gut microbiota and selection for AMR
- Understanding how resistance genes are transferred within the microbiome (including the gut, skin, respiratory and oral microbiomes), and between pathogenic and commensal bacteria, in both humans and animals.
- Investigating the role of the host immune response in selection and transmission of resistance bacteria.

- How do resistance bacteria and/or resistance genes in the environment (e.g. soil, feed, wastewater, freshwater, air, novel reservoirs) impact humans?
- What is the causality and directionality of spread of resistance genes between human and animal reservoirs?
- How does the frequency and duration of hospital admission and the volume of patient traffic between healthcare institutions contribute to dissemination of AMR between human and non-human reservoirs, and between humans, at both the individual and the population level?
- How does the transport of farm animals and the complex dynamics of the modern food chain contribute to dissemination of AMR between human and non-human reservoirs, between individuals, and on the population level?
- Exposure assessment of humans to indoor and outdoor environment and the role of various transmission pathways to colonization of AMR.
- What are critical control points at which interventions could substantially affect the spread of resistance? What are the most cost-effective prevention measures to reduce the transmission of resistance genes between human and non-human reservoirs, and between regional, national and international patient networks?
- What is the impact of human activities on the spread of antimicrobial agents, resistance genes, and multi-drug-resistant bacteria to water (both potable, and water in the environment), food and soils, and how can bio-remediative and bio-restorative interventions (waste management techniques) reduce the emergence and spread of AMR?

Following sub-topics are not in the purpose of the call:

- Development of new antimicrobial drugs that select less for resistance or block transmission
- Development or testing of diagnostic tools to monitor selection or transmission of AMR

1.2 Expected Impact:

It is expected that through international collaborations that combine complementary and synergistic research strengths, this JPIAMR call will increase the understanding of AMR transmission and facilitate the generation and application of new approaches to prevent and/or overcome antibiotic resistance. Proposals are expected to clearly define targets and milestones to deliver clinically relevant outcomes within the funding period.

2. Application:

2.1 Eligibility

Applicants must adhere to the specific regulations of the national funding organisations. Each transnational consortium submitting a proposal must involve:

- a minimum of three (3) eligible partners from three (3) different countries participating in the call
- a maximum of six (6) project participants
- a maximum of two (2) project participants funded by the same funding organisation.
- Project participants not eligible to be funded (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding countries) may be involved in projects if they secure their own funding and if their expertise is indispensable for reaching the objectives. However, the maximum number of six participants may not be exceeded, unless partners from under-represented countries are included (see below). The consortia should always consist of a majority of funded project participants.
- Project participants not eligible to be funded cannot be consortium coordinators and must accept all JPIAMR rules and guidelines just as funded members.
- Consortia including partners from countries that are to date underrepresented in the JPIAMR funding scheme may increase the total number of partners to 7. (The underrepresented countries are Poland, and Latvia.

2.2 Submission of joint transnational proposal

Submissions of proposals will be in two steps. In both cases, one joint proposal document (in English, and following the provided template) shall be prepared by the project participants of a joint transnational proposal, and must be submitted to the Joint Call Secretariat by the coordinator. A submission tool will be implemented in the JPIAMR website (http://www.jpiamr.eu/activities/joint-calls/3rd-joint-call-transmission-dynamics/). For details see also the **Guidelines for Applicants.**

The two-steps application process (pre-proposal, full proposal) will have the following timetable:

January 18th, 2016	**Publication of the JPIAMR ERA-NET Co-funded Call**
March 21st, 2016 (17:00 CET)	**Submission deadline for pre-proposals**
Mid May 2016	**Full proposal invitations send to project coordinators**
July 4th, 2016 (17:00 CET)	**Submission deadline for full proposals**
By October 15th, 2016	**Final funding decision to applicants**
End of 2016/Early 2017	**Start of funding**

2.3 Financial modalities and funding prerequisites

Funding is granted for a maximum of three years in accordance with national regulations. **Applicants must refer and adhere to their own specific national regulations and scientific remits as detailed in the National and Regional Requirements (see Annex B).**

The funds provided by the Parties are listed in the table below. The "virtual common pot model" shall apply for this transnational call. As such, each country will fund its own approved project partners. The proposals will be funded following the ranking list recommended by the Peer Review Panel.

Anticipated funding provided by each party

Country	***Name of Organisation***		***Contribution in million €***
Belgium	Fonds National de la Research Scientifique	FRS-FNRS	0,2M€
Belgium	Fonds voor Wetenschappelijk Onderzoek-Vlaanderen	FWO	0,2M€
Canada	Canadian Institutes of Health Research	CIHR	$3.6M CAD
Denmark	Innovationsfonden	DIF	1M€
France	The French National Research Agency	ANR	2M€
Germany	Bundesministerium für Bildung und Forschung (BMBF) / Deutsches Zentrum für Luft- und Raumfahrt (DLR)	BMBF/DLR	3M€
Israel	Chief Scientist Office, Ministry of Health	CSO-MOH	0,2M€
Italy	Ministry of Health	IT-MOH	0,8M€
Latvia	Valsts izglītības attīstības aģentūra	VIAA	0,2M€
Netherlands	Zorgonderzoek Nederland	ZON	1M€
Norway	The Research Council of Norway	RCN	2M€
Poland	Narodowe Centrum Nauki	NCN	0,25M€
Portugal	Fundação para a Ciência e a Tecnologia	FCT	0,4M€
Romania	National Authority for Scientific Research and Innovation	ANCSI	0.5 M€
Spain	National Institue of Health Carlos III	ISCIII	0,5M€
Spain	Ministerio de Economia y Competitividad	MINECO	0,5M€
Sweden	Swedish Research Council	SRC	4M€
Sweden	Forskningsrådet för miljö, areella näringar och samhällsbyggande	Formas	1M€
Switzerland	Swiss National Science Foundation	SNSF	0,6M€
Turkey	Turkiye bilimsel ve teknolojik arastirma kurumij	Tubitak	0,8M€
UK	Medical Research Council	MRC	3M€ (£2.16M)

Each funded consortium should provide a consortium agreement (CA) signed by all participants. The project consortium is strongly encouraged to sign this CA before the start of the project to clarify the potential IPR matters (such as licensing in, licensing out, patent and exploitation strategy), and in any case no later than six months after the official project start date. The points that must be addressed in the CA are detailed in the Annex C.

2.4 Contact persons

The only official communication line of the proposal is between the Joint Call Secretariat and the project coordinator. The project coordinator will be the person contacted by the Joint Call Secretariat during the application procedure, so he/she must forward this information to the other participants. Each funding organization has national contact persons who can be contacted for information about the specific national requirements (see Annex A).

Please note that country specific requirements might apply to this call. Compliance with the national/regional regulations specified in the country specific information is mandatory (See Annex B). We strongly advise you to contact your national/regional representative prior to submitting a pre-proposal.

3 Evaluation

Pre-proposals and full proposals will be assessed according to specific evaluation criteria (see below), using a common evaluation form. A scoring system from 0 to 5 will be used to evaluate the proposal's performance with respect to the different evaluation criteria.

Scoring system:

0: Failure. The proposal fails to address the criterion in question, or cannot be judged because of missing or incomplete information.

1: Poor. The proposal shows serious weaknesses in relation to the criterion in question.

2: Fair. The proposal generally addresses the criterion, but there are significant weaknesses that need corrections.

3: Good. The proposal addresses the criterion in question well but certain improvements are necessary.

4: Very good. The proposal addresses the criterion very well, but small improvements are possible.

5: Excellent. The proposal successfully addresses all aspects of the criterion in question.

Evaluation criteria:

1. Excellence
    a. Clarity and pertinence of the objectives
    b. Credibility of the proposed approach and methodology
    c. Soundness of the concept
    d. Innovative potential
    e. Competence and experience of participating research partners in the field(s) of the proposal (previous work in the field, specific technical expertise)
2. Impact

a. Potential of the expected results for future clinical, public health and/or other socio-economic health relevant applications including patients' needs
b. Added-value of transnational collaboration: gathering a critical mass of patients/biological material, sharing of resources (models, databases, diagnosis etc.), harmonization of data, sharing of specific know-how and/or innovative technologies.
c. Effectiveness of the proposed measures to exploit and disseminate the project results (including management of IPR), to communicate the project, and to manage research data where relevant
d. Industry and Patient Organization participation/engagement (when appropriate/applicable)

3. Quality and efficiency of the implementation
    a. Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks, resources and time-frame
    b. Complementarity of the participants within the consortium
    c. Appropriateness of the management structures and procedures, including risk and innovation management
    d. Concept for sustainability of infrastructures initiated by the project
    e. Budget and cost-effectiveness of the project (rational distribution of resources in relation to project's activities, partners responsibilities and time frame)

Sub-criteria 2a and 2b will be prioritized for assessing the impact of proposals (pre- and full proposal stage).

Evaluation scores will be awarded for the 3 main criteria, and not singularly for the different aspects listed below the criteria. The threshold for individual criteria will be 3. The maximum score that can be reached from all three criteria together is 15 points.

Annex A: National contact persons for each party providing funding

Country	*Funding org.*	*Contact person(s)*	*Email*
Belgium	FRS-FNRS	Arnaud Goolaerts	arnaud.goolaerts@frs-fnrs.be
Belgium	FWO	Olivier Boehme	eranet@fwo.be
Canada	CIHR	Olivier Jacob-Gravel Élisabeth Pagé	olivier.jacob-gravel@cihr-irsc.gc.ca elisabeth.page@crchudequebec.ulaval.ca
Denmark	DIF	Stine Larsen	stine.larsen@innofond.dk
France	ANR	Amélie Vergne Martine Batoux	JPI-AMRCalls@agencerecherche.fr
Germany	BMBF/DLR	Dr. Barbara Junker Dr. Martin Barth	barbara.junker@dlr.de M.Barth@dlr.de
Israel	CSO-MOH	Ahmi Ben-Yehudah	ahmi.by@moh.gov.il
Italy	IT-MOH	Dr. Raffaele Ruocco	r.ruocco@sanita.it
Latvia	VIAA	Dr Maija Bundule Dr Uldis Berkis	Maija.Bundule@viaa.gov.lv Uldis.Berkis@viaa.gov.lv
Netherlands	ZON	Thera Habben Jansen	HabbenJansen@zonmw.nl
Norway	RCN	Sonja Prehn Dyveke Hetland	sp@rcn.no dhe@rcn.no
Poland	NCN	Jerzy Fraczek Malwina Gębalska,	jerzy.fraczek@ncn.gov.pl malwina.gebalska@ncn.gov.pl
Portugal	FCT	Marta Abrantes Anabela Isidro	marta.abrantes@fct.pt anabela.isidro@fct.pt
Romania	ANCSI	Ioana Ispas	Ioana.ispas@ancs.ro
Spain	ISCIII	Irene Sánchez	Isanchezgarcia@isciii.es
Spain	MINECO	Estrella Fernandez	amr@mineco.es
Sweden	SRC	Anh Thu Nguyen Hoang Patriq Fagerstedt	anhthu.nguyenhoang@vr.se patriq.fagerstedt@vr.se
Sweden	Formas	Mattias Norrby	mattias.norrby@formas.se
Switzerland	SNSF	Barbara Flückiger	barbara.flueckiger@snf.ch
Turkey	Tubitak	Burak Barut Emine Derebay	burak.barut@tubitak.gov.tr emine.derebay@tubitak.gov.tr
UK	MRC	Ruth Kelly Ghada Zoubiane	amr@headoffice.mrc.ac.uk

Annex B: National and Regional Requirements

Belgium – FRS-FNRS

Funding of industrial partners eligible?	No
Participation of industry required?	No
Maximum funding	200.000 EUR/1 Project/3yrs
Eligible costs	See national regulations (http://www.ncp.frs-fnrs.be/index.php/appels/era-nets)
Additional documents required	No
Other national restrictions	See national regulations (http://www.ncp.frs-fnrs.be/index.php/appels/era-nets)

Belgium – FWO

Funding of industrial partners eligible?	No
Participation of industry required?	No
Maximum funding	200.000 EUR /1 project/ 3 years
Eligible costs	See national regulations
Additional documents required	No
Other national restrictions	See national regulations

Canada CIHR

Funding of industrial partners eligible?	No
Participation of industry required?	No
Maximum funding	CIHR will contribute up to $200,000 per year per application, enough to fund approximately six (6) grants.
Eligible costs	Recipients should review the Use of Grant Funds section of the Tri-Agency (CIHR, NSERC and SSHRC) Financial Administration Guide for a complete listing and description of allowable costs and activities.
Additional documents required	Canadian applicants invited to submit a full application must complete a CIHR application and submit it using ResearchNet. The deadline for submission of this application is the same as the Full Application deadline to Joint Action Secretariat. The purpose of this additional application to CIHR is to provide CIHR with an Operating Budget for the project, with the amounts quoted in Canadian dollars, and a complete justification for funds requested.
Other national restrictions	The Nominated Principal Applicant (NPA) must be an independent Researcher. The NPA must have an academic or research appointment at a CIHR eligible institution (See Institutional Eligibility Requirements for eligibility process and associated timelines. No indirect costs will be covered

Denmark DIF

Funding of industrial partners eligible?	Yes
Participation of industry required?	No
Maximum funding	No
Eligible costs	See national guidelines: http://fivu.dk/en/research-and-innovation/councils-and-commissions/the-danish-council-for-strategic-research/dsf-filer/guidelines-transnational-calls-september-2013.pdf
Additional documents required	See national guidelines
Other national restrictions	See national guidelines

France ANR

Funding of industrial partners eligible?	Yes
Participation of industry required?	No
Maximum funding	Minimum amount per partner: 15 000 €. Maximum amount: 250 000 €
Eligible costs	Personnel, Consumables, Animals, Subcontracts (if costs<50% eligible costs), Equipment, Travel. See French Annex for details (http://anr.fr/JPI-AMR-2016)
Additional documents required	No
Other national restrictions	

Germany BMBF/DLR

Funding of industrial partners eligible?	Yes
Participation of industry required?	No
Maximum funding	No
Eligible costs	See national guidelines
Additional documents required	No
Other national restrictions	See national guidelines

Israel CSO-MOH

Funding of industrial partners eligible?	Only on their own funding
Participation of industry required?	No
Maximum funding	Up to 100,000 euros per project
Eligible costs	Personnel (students, technicians, applicants excluded); Animals, Materials and consumables; Travel (up to 10%); Institutional overhead 10%. No permanent equipment.
Additional documents required	Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including detailed budget distribution. No submission of abstract can lead to disqualification of the whole application, as well as the consortium.
Other national restrictions	Research will not be funded simultaneously by CSO-MOH on more than one grant (ERA-NET or national). Researchers can only apply for one grant from any ERA-NET funded by CSO-MOH or submit only one proposal for any single programme. Please see detailed instructions at www.health.gov.il/research-fund

Italy IT-MOH

Funding of industrial partners eligible?	Only Scientific Institutes for Research, Hospitalization and Health Care (Istituti di Ricovero e Cura a Carattere Scientifico pubblici e privati, IRCCS) are eligible. No industrial partners are eligible.
Participation of industry required?	No
Maximum funding	Max 250.000 € per project
Eligible costs	Only costs generated during the lifetime of the project can be eligible. Personnel (only ad hoc contracts/consultants/fellowship, max 50% of the requested fund); travel costs and subsistence allowances (max 10% of the requested fund); equipment (rent/leasing only, no limit), consumables (no limit), dissemination of results (publications, meetings/workshops etc.- max 1% of the requested fund); data handling and analysis (no limit); overhead (maximum 10% of the requested fund). (All according to the national regulations). Travel expenses and subsistence allowances associated with training activities only linked to the project
Additional documents required	The simultaneous participation in proposals submitted to different transnational research calls, funded by the Ministero della Salute, is not allowed to Italian Principal Investigators or other research team members. In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicants prior to the submission of the pre-proposals. To this end, it is mandatory that the applicants fill out and return a pre-eligibility (Italy MOH mandatory pre-eligibility check form) check form trough IRCCS Scientific Directorate or Regional Office Health Research using WFR System 10 days before submitting their pre-proposals to the Joint Call Secretariat. It is strongly recommended that the form, completed and duly signed, is returned at least 10 working days before the pre-proposal submission deadline. Applicants will be sent a written notification of their eligibility status.
Other national restrictions	After the JPI-AMR JTC 2016 peer review has been completed and the final (scientific) ranking list has been performed and endorsed by the Call Steering Committee, the Ministry of Health will invite the principal investigators of the projects approved for funding to enter the formal national negotiations (according to national regulations). The funding of this projects are under the Ricerca Corrente IRCCS rules.

Latvia VIAA

Funding of industrial partners eligible?	Yes, eligible Enterprises entered into the Latvian Commercial registry, assumed they are eligible to do the specific research and are in possession of necessary resources in Latvia. Limitations of EU legislation apply (R651/2014) together with financial reporting and audit requirements
Participation of industry required?	No
Maximum funding	Per partner: 70.000 EUR/year, i.e. maximum grant per partner 210.000 EUR for a 3-year project. Can be increased by eventual top-up funding, ca 10%
Eligible costs	• Personnel incl. social tax (maximum rates apply) • Consumables • Animals • Subcontracts (up to 25%) needs detailed justification, subject to approval. Includes all external services. • Equipment (only depreciation costs) • Replaceable un fully consumable during project elements of equipment e.g. electrodes fully • Travel (according to travel plan) • Indirect costs (up to 25% of direct costs exempt subcontracting) Costs must be research and innovation costs, there is no support for other activities
Additional documents required	No
Other national restrictions	See Provisions of the Cabinet of Ministers: http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma They should be followed without any exception. All limits and conditions contained in the Provisions in relation to ERA-NET or ERA-NET Cofund are an eligibility criteria for funding

Netherlands ZON

Funding of industrial partners eligible?	Please consult http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/ or your national contact person
Participation of industry required?	No
Maximum funding	1 Dutch participant in the consortium: max €300.000 2 Dutch participants in the consortium: max €450.000 (for the both of them together) 1 Dutch coordinator in the consortium: max €350.000 1 Dutch coordinator + 1 Dutch participant in the consortium: max €500.000 (for the both of them together)
Eligible costs	Please consult http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/ or your national contact person
Additional documents required	Please consult http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/ or your national contact person
Other national restrictions	Please consult http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/ or your national contact person

Norway RCN

Funding of industrial partners eligible?	Yes
Participation of industry required?	No
Maximum funding	0,8 M€ for the total 3 year period
Eligible costs	2 M€ for the total 3 year period
Additional documents required	No
Other national restrictions	See national guidelines. Please note that you can only be the Project manager for one project in this call. However you can be partner on several applications

Poland NCN

Funding of industrial partners eligible?	Yes
Participation of industry required?	No
Maximum funding	€250 000
Eligible costs	See Annex to NCN Council's Resolution on funding granted within calls for proposals for international research projects: https://ncn.gov.pl/sites/default/files/pliki/uchwaly-rady/2015/uchwala84_2015-zal1.pdf (p. 5-12). Overhead costs must not exceed a maximum of 30% of the total eligible costs (excl. equipment) and may not be increased during the course of a research project.
Additional documents required	On the full proposal stage you will be requested to complete the following table: http://ncn.gov.pl/pliki/jpi-ec-abr_budget_table.xlsx.
Other national restrictions	Who can apply? Any researcher, with a doctoral degree, employed at a Polish institution may act as a Principal Investigator. Only proposals involving basic research (original experimental or theoretical research work undertaken primarily to acquire new knowledge of the underlying foundations of phenomena and observable facts) may be submitted in response to the call for proposals. Applicants are obliged to adhere to the rules included in Annex to NCN Council's Resolution on funding granted within calls for proposals for international research projects: https://ncn.gov.pl/sites/default/files/pliki/uchwaly-rady/2015/uchwala84_2015-zal1.pdf

Portugal FCT

Funding of industrial partners eligible?	Yes
Participation of industry required?	No
Maximum funding	Max 250.000 EUR /Project if the coordinator is a PT team; max 150.000 EUR /Project if PT team(s) is (are) only participant(s). See National Regulations: https://www.fct.pt/apoios/projectos/regulamento.phtml.en
Eligible costs	See National Regulations: https://www.fct.pt/apoios/projectos/regulamento.phtml.en
Additional documents required	Each Portuguese participant has to send to the Call National Contact Point a Statement of Commitment. See details in http://www.fct.pt/apoios/cooptrans/eranets/amr/index.phtml.en
Other national restrictions	See National Regulations: https://www.fct.pt/apoios/projectos/regulamento.phtml.en and check JPI-EC-AMR webpage in FCT's website http://www.fct.pt/apoios/cooptrans/eranets/amr/index.phtml.en

Romania ANCSI

Funding of industrial partners eligible?	No
Participation of industry required?	No
Maximum funding	Up to 200.000 EUR/partner Up to 250.000 EUR/coordinator
Eligible costs	See national guidelines http://uefiscdi.gov.ro/articole/4271/Dezbatere-publica-pachet-informatii-proiecte-ERA-NET-ERA-NET-Cofund.html
Additional documents required	No
Other national restrictions	See national guidelines http://uefiscdi.gov.ro/articole/4271/Dezbatere-publica-pachet-informatii-proiecte-ERA-NET-ERA-NET-Cofund.html

Spain ISCIII

Funding of industrial partners eligible?	No
Participation of industry required?	No
Maximum funding	Up to 100.000 EUR/partner Up to 150.000 EUR/coordinator
Eligible costs	See national guidelines
Additional documents required	No
Other national restrictions	See national guidelines

Spain MINECO

Funding of industrial partners eligible?	No. Although enterprises will not be funded through the APCIN Call, the Spanish industrial sector is much welcome to participate in the transnational consortia using their own funds.
Participation of industry required?	No
Maximum funding	See national guidelines
Eligible costs	- Personnel costs for temporary contracts (fellowships are not eligible). - Current costs such as those incurred in purchasing small scientific and IT equipment, disposable materials, travelling expenses and other costs that can be properly justified as necessary to carry out the proposed activities. - Indirect costs or clinical assays are not eligible for funding.
Additional documents required	No

Sweden FORMAS

Funding of industrial partners eligible?	No
Participation of industry required?	No
Maximum funding	No
Eligible costs	The same as for applications for Formas project grants
Additional documents required	No
Other national restrictions	See national guidelines

Sweden SRC

Funding of industrial partners eligible?	No
Participation of industry required?	No
Maximum funding	No
Eligible costs	The same as for applications for SRC project grants
Additional documents required	No
Other national restrictions	See national guidelines

Switzerland SNSF

Funding of industrial partners eligible?	No
Participation of industry required?	No
Maximum funding	No
Eligible costs	See regular SNSF guidelines
Additional documents required	No
Other national restrictions	Projects must fit with the goals of the National Research Programme “Antimicrobial Resistance” (NRP 72): www.nrp72.ch

Turkey Tubitak

Funding of industrial partners eligible?	Yes
Participation of industry required?	No
Maximum funding	120.000 TL/year with a maximum of 36 months
Eligible costs	Scholarships, materials, machines excluding infrastructures
Additional documents required	Electronic application print out, If required, committee of ethics approval form, Possession of rights declaration form, For projects submitted previously, project proposal revision information form, For non-Turkish citizens involved in the project as a project manager, researcher or advisor, official payment approval form, Support letters (if applicable), Official permits (if required)
Other national restrictions	No

UK

Funding of industrial partners eligible?	No
Participation of industry required?	No
Maximum funding	Individual projects led by up to one UK group can request up to £300,000 per project and projects led by two groups can request up to £400,000 per project
Eligible costs	Follow MRC guidance
Additional documents required	No
Other national restrictions	UK Researchers must contact AMR@headoffice.mrc.ac.uk before submitting to ensure they are eligible to apply

Annex C: Guidelines for Consortium Agreement for Project Participants

Each consortium should provide a Consortium Agreement (CA) signed by all participants before the start of the project to clarify the potential IPR matters (such as licensing in, licensing out, and patent and exploitation strategy). The CA must address (as a minimum), the following points:

- common start date and duration of the research project
- organisation and management of the project
- role and responsibilities of each partner, resources and funding
- confidentiality and publishing
- Intellectual Property Rights
- decision making within the consortium
- handling of internal disputes
- the liabilities of the research partners towards one another (including the handling of default of contract).

Any issues regarding funding are a bilateral matter between each project partner and the relevant funding organisation and should be excluded from the CA. The CA together with any other information required by national/regional regulations must be made available on request to the national funding agencies.